As of Nov 19, 2026, 0 of 1 active firms rate MED a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MED EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.06 – $-0.06 · 1 analysts · -68% YoY
Next period, 1 analysts expect MEDIFAST INC to earn $-0.06 a share (range $-0.06 – $-0.06), versus $-0.19 a year earlier. Full-year consensus is $-0.86, growing to $-0.04 the year after.
REVENUE · NEXT QUARTER
$70.1M
Range $70.1M – $70.1M · 1 analysts · -8% YoY
Revenue is expected to reach $70.1M (range $70.1M – $70.1M), -7.8% year-over-year. Full-year consensus is $288.5M, rising to $274.5M next year.
Top analysts covering MEDIFAST INC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MED.
#1
Linda Bolton Weiser
DA Davidson · Rank #518
Neutral
$16.50+35.0% to target
Overall win rate
29%
+ Follow
#2
Jim Salera
Stephens & Co. · Rank #576
Neutral
$12.00-1.8% to target
Overall win rate
19%
+ Follow
MED stock forecast FAQ
What is MED's average 12-month price target?+
The 1 active firms with a live target average $12.00 for MEDIFAST INC over the next 12 months, ranging from a $12.00 high to a $12.00 low, as of Nov 19, 2026.
Is MED stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover MED?+
1 active firms have a recognized rating on MEDIFAST INC as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MED?+
Among analysts who currently cover MED, Linda Bolton Weiser of DA Davidson has the strongest overall Quantellect track record (Rank #518). Their current call is Neutral with a $16.50 target.
What is MEDIFAST INC's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.06 – $-0.06) across 1 analysts. Full-year EPS is projected at $-0.86, rising to $-0.04 the following year.
How much revenue is MEDIFAST INC expected to report next quarter?+
Consensus revenue is $70.1M (range $70.1M – $70.1M). Full-year revenue is projected at $288.5M, growing to $274.5M next year.
Have analysts been upgrading or downgrading MED lately?+
As of Nov 19, 2026, 0 of 1 active firms rate MED a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MED calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.